Yeleswaram Krishnaswamy
Yeleswaram Krishnaswamy, CDO, reported an open-market or private sale at Rapport Therapeutics, Inc. involving 16201.000000 shares for an estimated $827184.18. Reported holdings after the transaction were 195862.000000 shares. The stored filing text includes a detected 10b5-1 reference.
- Trade date
- Aug 25, 2026
- Filing date
- Aug 26, 2026
How reported position traded is calculated
Shares sold ÷ (holdings after + shares sold). Estimated position before: 212,063 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
RAPP price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- Sell Code S
- Identifier
- 0001193125-26-368244 Common Stock
- Transaction date
- Aug 25, 2026 Filed Aug 26, 2026, 08:00 PM · 1d delay
- Shares
- 16,201 sh $51.06 per share
- Estimated value
- -$827k Computed from shares × price
- Holdings after
- 195,862 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
0 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 1
Filing reported within two business days of the transaction. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Development Officer
- F1
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.25 inclusive. The Reporting Person undertakes to provide…
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.88 inclusive. The Reporting Person undertakes to provide…
- F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.91 to $51.39 inclusive. The Reporting Person undertakes to provide…
0 other transactions
0 recent txs